Fig. 5: Inhibition of EGFR-KDD is maximally achieved by blocking both intra- and inter-molecular dimerization.

a YAMC cells were starved for 12 h and treated with afatinib (10 nM in serum-free medium) and cetuximab (10 µg/ml in serum-free medium) for 3 h 45 min, and then were treated with EGF (50 ng/mL in serum-free medium) for 15 min. The cells were harvested and analyzed by Western blot. b Cell Viability Assay was performed in mIL3-independent Ba/F3 cells stably expressing EGFR-KDD, Ex19Del and L858R supplemented with 0.5% FBS. c Cell Viability Assay was performed in mIL3-independent Ba/F3 cells stably expressing EGFR-KDD, Ex19Del, and L858R supplemented with 10% FBS. For a, n = 3 experiments were repeated independently with similar results. For b and c, n = 3 biologically independent replicates were examined over three independent experiments with similar results. Data are presented as mean values ± SD. Results in a, b and c are the representative of three independent experiments. Source data are provided as a Source Data file.